TCI Wealth Advisors’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-125
Closed -$31K 2707
2022
Q3
$31K Buy
125
+101
+421% +$27.3K 0.01% 512
2022
Q2
$6K Hold
24
﹤0.01% 1432
2022
Q1
$8K Sell
24
-3
-11% -$923 ﹤0.01% 1283
2021
Q4
$10K Hold
27
﹤0.01% 1214
2021
Q3
$9K Hold
27
﹤0.01% 1211
2021
Q2
$8K Sell
27
-10
-27% -$3.07K ﹤0.01% 1159
2021
Q1
$12K Buy
37
+10
+37% +$3.2K 0.01% 789
2020
Q4
$9K Buy
27
+3
+13% +$830 ﹤0.01% 695
2020
Q3
$7K Sell
24
-2
-8% -$576 ﹤0.01% 693
2020
Q2
$6K Sell
26
-6
-19% -$1.21K ﹤0.01% 711
2020
Q1
$5K Sell
32
-2
-6% -$332 ﹤0.01% 741
2019
Q4
$6K Sell
34
-17
-33% -$3.15K ﹤0.01% 831
2019
Q3
$9K Buy
51
+7
+16% +$1.51K ﹤0.01% 679
2019
Q2
$11K Hold
44
0.01% 613
2019
Q1
$13K Hold
44
0.01% 587
2018
Q4
$14K Hold
44
0.01% 558
2018
Q3
$20K Hold
44
0.01% 509
2018
Q2
$18K Hold
44
0.01% 511
2018
Q1
$13K Hold
44
0.01% 578
2017
Q4
$8K Hold
44
﹤0.01% 691
2017
Q3
$7K Hold
44
﹤0.01% 680
2017
Q2
$6K Hold
44
﹤0.01% 733
2017
Q1
$6K Hold
44
﹤0.01% 696
2016
Q4
$5K Sell
44
-40
-48% -$4.63K ﹤0.01% 793
2016
Q3
$11K Buy
84
+50
+147% +$5.99K 0.01% 565
2016
Q2
$4K Hold
34
﹤0.01% 804
2016
Q1
$3K Buy
+34
New +$2.87K ﹤0.01% 882

Other funds holding ABMD

TCI Wealth Advisors's ABMD Position: Q4 2022 in Review

TCI Wealth Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 125 shares — an estimated $31K sold.

TCI Wealth Advisors first reported a position in ABMD in Q1 2016 and held it in 27 quarters. The position peaked at $31K in Q3 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • TCI Wealth Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 125 Abiomed Inc shares in Q4 2022, an estimated $31K.
  • TCI Wealth Advisors first reported a position in Abiomed Inc in Q1 2016 and held it in 27 quarters.
  • TCI Wealth Advisors's Abiomed Inc position peaked at $31K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on TCI Wealth Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.